What's new

Human medicines European public assessment report (EPAR): Myalepta, metreleptin, Date of authorisation: 29/07/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 12, 2025 0

Human medicines European public assessment report (EPAR): Myalepta, metreleptin,...

EMEA-000802-PIP01-09

EMEA-000802-PIP01-09

Feb 11, 2025 0

EMEA-000802-PIP01-09

Herbal medicinal product: Boldi foliumArray, C: ongoing call for scientific data

Herbal medicinal product: Boldi foliumArray, C: ongoing...

Feb 11, 2025 0

Herbal medicinal product: Boldi foliumArray, C: ongoing call for scientific data

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Date of authorisation: 14/10/1998, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,...

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Date of authorisation: 16/10/1998, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,...

Human medicines European public assessment report (EPAR): Repaglinide Teva, repaglinide, Date of authorisation: 28/06/2009, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Repaglinide Teva, repa...

Webinar on PMS Project Made Easy: Summary of activities and Practical Tips for SMEs, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 February 2025, 14:00 (CET) to 24 February 2025, 16:00 (CET)

Webinar on PMS Project Made Easy: Summary of activities...

Feb 11, 2025 0

Webinar on PMS Project Made Easy: Summary of activities and Practical Tips for S...

Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Date of authorisation: 26/08/1997, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Aprovel, irbesartan, D...

Executive Steering Group on Shortages and Safety of Medicinal Products

Executive Steering Group on Shortages and Safety of Med...

Feb 11, 2025 0

Executive Steering Group on Shortages and Safety of Medicinal Products

Human medicines European public assessment report (EPAR): Ultibro Breezhaler, indacaterol,glycopyrronium bromide, Date of authorisation: 19/09/2013, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Ultibro Breezhaler, in...

Supporting innovation

Supporting innovation

Feb 11, 2025 0

Supporting innovation

Human medicines European public assessment report (EPAR): Armisarte (previously Pemetrexed Actavis), pemetrexed, Date of authorisation: 18/01/2016, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Armisarte (previously ...

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (17...

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, ...

Consolidated 3-year work plan for the Emergency Task Fo...

Feb 11, 2025 0

Consolidated 3-year work plan for the Emergency Task Force (ETF)

Minutes of the COMP meeting 3-5 December 2024

Feb 11, 2025 0

Minutes of the COMP meeting 3-5 December 2024

Human medicines European public assessment report (EPAR): Korjuny, catumaxomab, Date of authorisation: 10/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Korjuny, catumaxomab, ...

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Hetronifly, serplulima...

Agenda of the CVMP meeting 11-13 February 2025

Feb 11, 2025 0

Agenda of the CVMP meeting 11-13 February 2025

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025 0

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, D...

Jakavi-H-C-002464-X-0070-G : EPAR - Assessment report -...

Feb 11, 2025 0

Jakavi-H-C-002464-X-0070-G : EPAR - Assessment report - Variation

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 10, 2025 0

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab...

Applications for new human medicines under evaluation: ...

Feb 10, 2025 0

Applications for new human medicines under evaluation: February 2025

Medicines for human use under evaluation

Medicines for human use under evaluation

Feb 10, 2025 0

Medicines for human use under evaluation

54
55
56
57
58

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.